Breakthroughs in therapies for NASH and remaining challenges

Area of Science:

• Hepatology
• Gastroenterology
• Pharmacology

Background:

• Non-alcoholic steatohepatitis (NASH) has evolved from a condition of limited recognition to a leading cause of chronic liver disease.
• The clinical impact and unmet medical need in NASH are now widely acknowledged.
• Despite the absence of approved therapies, significant advancements have been made.

Purpose of the Study:

• To review recent breakthroughs in non-alcoholic steatohepatitis (NASH) research.
• To highlight progress in understanding NASH pathogenesis and identifying therapeutic targets.
• To discuss the development of surrogate outcomes and non-invasive biomarkers for clinical trials.

Main Methods:

• Review of recent scientific literature and clinical trial data in NASH.
• Analysis of advancements in understanding NASH pathogenesis.
• Evaluation of regulatory acceptance of surrogate outcomes for therapeutic trials.
• Assessment of non-invasive measurements for early-stage clinical trials.

Main Results:

• Major breakthroughs have occurred, paving the way for future therapeutic successes in NASH.
• Numerous pharmacological targets have been identified due to improved understanding of NASH pathogenesis.
• Key surrogate outcomes are accepted by regulatory agencies, establishing a path for drug registration.
• Early-stage trials using non-invasive measurements have yielded promising efficacy results for compounds in late-stage development.

Conclusions:

• The unmet medical need in NASH is significant, and therapeutic options are emerging.
• Advancements in trial design, including surrogate outcomes and non-invasive biomarkers, are crucial for developing effective NASH treatments.
• Ongoing research aims to refine histological assessments and predictive biomarkers to facilitate successful clinical trials and provide patients with new therapeutic options.